A double-blind trial of disodium cromoglycate (Intal) in the treatment of bronchial asthma.
The result of a double-blind crossover trial with disodium cromoglycate (Intal) in 22 patients, nine with extrinsic asthma and 13 with intrinsic asthma, is reported. While eight extrinsic asthmatics showed considerable symptomatic improvement, only five of the intrinsic group improved while on disodium cromoglycate. Twelve out of 13 patients with symptomatic improvement had associated decrease in airway obstruction as measured by the FEV(1).It is concluded that disodium cromoglycate is useful in the treatment of asthma, particularly of the extrinsic type.
D000328:Adult; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003371:Cough / Q000188:drug therapy; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D004485:Eczema / Q000150:complications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011241:Prednisone / Q000627:therapeutic use; D012138:Respiratory Therapy; D012220:Rhinitis / Q000150:complications; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications; D012907:Smoking / Q000150:complications; D013183:Sputum / Q000032:analysis
D001993:Bronchodilator Agents; D010919:Placebos; D004205:Cromolyn Sodium; D011241:Prednisone